R-Pharm does not plan to release AstraZeneca vaccine for the Russian market – Economy and business
GELENDZHIK, October 5. / TASS /. The pharmaceutical company R-Pharm has yet to start producing the AstraZeneca vaccine for the Russian market. Vasily Ignatiev, general director of R-Pharma, told TASS on the sidelines of the Biotechmed forum.
“Frankly speaking, there are no such plans yet. We are ready to move in this direction,” Ignatiev said.
On September 17, First Deputy Industry and Trade of the Russian Federation Vasily Osmakov announced that the R-Pharm company had begun production of the AstraZeneca coronavirus vaccine for export. Earlier, the Russian Direct Investment Fund said that AstraZeneca and R-Pharm had agreed on the production of a vaccine in Russia. It was assumed that Russia will become a platform for the production and supply of vaccines to the markets of 30 countries.
About company
The main activities of the R-Pharm Group of Companies are the production of finished medicines, research and development of innovative drugs and technologies, the introduction of modern medicines to the market, as well as education and training of specialists for the pharmaceutical industry and healthcare. The company was founded in 2001 and operates in the Russian Federation, as well as in the CIS, USA, Germany, Japan and other countries.